Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shenzhen Chipscreen Biosciences Ltd.

www.chipscreen.com

Latest From Shenzhen Chipscreen Biosciences Ltd.

Asia Deal Watch: Daiichi Sankyo Acquires Partial Asian Rights To Three Astellas Drugs

Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.

Deals Business Strategies

Trend Revising? Biotech IPOs Slow Sharply In HK While Shanghai's STAR Shines

Just one year ago, biotechs were queuing up to list in Hong Kong following a relaxation of rules, but now many are postponing plans or simply shifting away, impacted by the market's low valuations, fast-changing environment and surprisingly strong competition from a new Shanghai trading section.  

Financing China

Trade War Expansion? STAR Board Aims To Keep Lucrative China Biotech IPOs At Home

China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival to similar bourses in the US and Hong Kong. But some are cautioning that local regulators and investors will need to step up if the so-called China Nasdaq is to gain traction.

China Financing

Tough Going Forces Chinese Biotechs To Form Domestic Alliances

Deals among domestic Chinese biotechs are growing fast, reflecting a need to huddle up amid tightening scrutiny over biotech deal-making and an unusually competitive immuno-oncology market.

Deals Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Shenzhen Chipscreen Biosciences Ltd.
  • Senior Management
  • Xian-Ping Lu, PhD, Pres. & CSO
    Zhiqian Ning, PhD, Dir., R&D
  • Contact Info
  • Shenzhen Chipscreen Biosciences Ltd.
    Phone: (86) 755 26957317
    Ste. C301, Rsch. Inst. of Tsingua Univ.
    High-Tech Park
    P.O. Box 28 Shenzhen,
    China
UsernamePublicRestriction

Register